{"transactions":[{"id":687422,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":23537,"kind":"person","name":"Haas Jason","position":1,"cik":"0001883821","reported_name":"Haas Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2026-08-14T21:04:53.000Z","date":"2026-08-12","kind":"exercise","planned":false,"acquired":false,"shares":6138,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This Option was previously reported as a Grant of 5,907 shares on June 29, 2022, at an exercise price of $88.48 per share, which becomes exercisable in three successive annual installments upon completion of each calendar year of service beginning on the grant date, but was adjusted pursuant to the OmniAb Inc. separation from the issuer."}],"balance_after":0,"derivative":{"exercise_price":51.56,"expiration_date":"2032-06-29","underlying":"Common Stock","underlying_shares":6138},"source":{"system":"sec-edgar","filing":"0002001011-26-000114","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000114/edgardoc.xml","form_type":"4"}},{"id":687421,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":23537,"kind":"person","name":"Haas Jason","position":1,"cik":"0001883821","reported_name":"Haas Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-14T21:04:53.000Z","date":"2026-08-12","kind":"sale","planned":false,"acquired":false,"shares":7138,"price":292.8078,"value":2090062.0764,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $292.5000 to $292.8550. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":3981,"source":{"system":"sec-edgar","filing":"0002001011-26-000114","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000114/edgardoc.xml","form_type":"4"}},{"id":687420,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":23537,"kind":"person","name":"Haas Jason","position":1,"cik":"0001883821","reported_name":"Haas Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-14T21:04:53.000Z","date":"2026-08-12","kind":"exercise","planned":false,"acquired":true,"shares":6138,"price":51.56,"value":316475.28,"ownership":{"direct":true},"balance_after":11119,"source":{"system":"sec-edgar","filing":"0002001011-26-000114","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000114/edgardoc.xml","form_type":"4"}},{"id":738588,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":23537,"kind":"person","name":"Haas Jason","position":1,"cik":"0001883821","reported_name":"Haas Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2026-06-16T01:06:58.000Z","date":"2026-06-12","kind":"exercise","planned":false,"acquired":false,"shares":1000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This Option was previously reported as a Grant of 5,907 shares on June 29, 2022, at an exercise price of $88.48 per share, which becomes exercisable in three successive annual installments upon completion of each calendar year of service beginning on the grant date, but was adjusted pursuant to the OmniAb Inc. separation from the issuer."}],"balance_after":6138,"derivative":{"exercise_price":51.56,"expiration_date":"2032-06-29","underlying":"Common Stock","underlying_shares":1000},"source":{"system":"sec-edgar","filing":"0002001011-26-000104","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000104/edgardoc.xml","form_type":"4"}},{"id":738587,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":23537,"kind":"person","name":"Haas Jason","position":1,"cik":"0001883821","reported_name":"Haas Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2026-06-16T01:06:58.000Z","date":"2026-06-12","kind":"exercise","planned":false,"acquired":false,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This Option was previously reported as a Grant of 5,907 shares on June 29, 2022, at an exercise price of $88.48 per share, which becomes exercisable in three successive annual installments upon completion of each calendar year of service beginning on the grant date, but was adjusted pursuant to the OmniAb Inc. separation from the issuer."}],"balance_after":7138,"derivative":{"exercise_price":51.56,"expiration_date":"2032-06-29","underlying":"Common Stock","underlying_shares":3000},"source":{"system":"sec-edgar","filing":"0002001011-26-000104","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000104/edgardoc.xml","form_type":"4"}},{"id":738586,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":23537,"kind":"person","name":"Haas Jason","position":1,"cik":"0001883821","reported_name":"Haas Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-16T01:06:58.000Z","date":"2026-06-12","kind":"sale","planned":false,"acquired":false,"shares":3461,"price":256.0781,"value":886286.3041,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $256.0000 to $256.5100. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":4981,"source":{"system":"sec-edgar","filing":"0002001011-26-000104","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000104/edgardoc.xml","form_type":"4"}},{"id":738585,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":23537,"kind":"person","name":"Haas Jason","position":1,"cik":"0001883821","reported_name":"Haas Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-16T01:06:58.000Z","date":"2026-06-12","kind":"sale","planned":false,"acquired":false,"shares":3000,"price":255.0113,"value":765033.9,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $255.0000 to $255.2900. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":8442,"source":{"system":"sec-edgar","filing":"0002001011-26-000104","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000104/edgardoc.xml","form_type":"4"}},{"id":738584,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":23537,"kind":"person","name":"Haas Jason","position":1,"cik":"0001883821","reported_name":"Haas Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-16T01:06:58.000Z","date":"2026-06-12","kind":"exercise","planned":false,"acquired":true,"shares":1000,"price":51.56,"value":51560.0,"ownership":{"direct":true},"balance_after":11442,"source":{"system":"sec-edgar","filing":"0002001011-26-000104","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000104/edgardoc.xml","form_type":"4"}},{"id":738583,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":23537,"kind":"person","name":"Haas Jason","position":1,"cik":"0001883821","reported_name":"Haas Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-16T01:06:58.000Z","date":"2026-06-12","kind":"exercise","planned":false,"acquired":true,"shares":3000,"price":51.56,"value":154680.0,"ownership":{"direct":true},"balance_after":10442,"source":{"system":"sec-edgar","filing":"0002001011-26-000104","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000104/edgardoc.xml","form_type":"4"}},{"id":745413,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":23537,"kind":"person","name":"Haas Jason","position":1,"cik":"0001883821","reported_name":"Haas Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2026-06-09T23:35:49.000Z","date":"2026-06-05","kind":"grant","planned":false,"acquired":true,"shares":2938,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 5, 2026. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant."}],"balance_after":2938,"derivative":{"exercise_price":237,"expiration_date":"2036-06-05","underlying":"Common Stock","underlying_shares":2938},"source":{"system":"sec-edgar","filing":"0002001011-26-000097","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000097/edgardoc.xml","form_type":"4"}},{"id":745412,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":23537,"kind":"person","name":"Haas Jason","position":1,"cik":"0001883821","reported_name":"Haas Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-09T23:35:49.000Z","date":"2026-06-05","kind":"grant","planned":false,"acquired":true,"shares":836,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 5, 2026. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant."}],"balance_after":7442,"source":{"system":"sec-edgar","filing":"0002001011-26-000097","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000097/edgardoc.xml","form_type":"4"}},{"id":784138,"issuer":{"id":4850,"kind":"organization","name":"Odyssey Therapeutics, Inc."},"owners":[{"id":23537,"kind":"person","name":"Haas Jason","position":1,"cik":"0001883821","reported_name":"Haas Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-05-12T00:32:41.000Z","date":"2026-05-08","kind":"purchase","planned":false,"acquired":true,"shares":1000,"price":20,"value":20000.0,"ownership":{"direct":true},"balance_after":62908,"source":{"system":"sec-edgar","filing":"0001193125-26-217600","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1882782/000119312526217600/ownership.xml","form_type":"4"}},{"id":1116952,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":23537,"kind":"person","name":"Haas Jason","position":1,"cik":"0001883821","reported_name":"Haas Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2025-06-10T23:20:53.000Z","date":"2025-06-06","kind":"grant","planned":false,"acquired":true,"shares":5783,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 6, 2025. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant."}],"balance_after":5783,"derivative":{"exercise_price":105.99,"expiration_date":"2035-06-06","underlying":"Common Stock","underlying_shares":5783},"source":{"system":"sec-edgar","filing":"0002001011-25-000040","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101125000040/edgardoc.xml","form_type":"4"}},{"id":1116951,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":23537,"kind":"person","name":"Haas Jason","position":1,"cik":"0001883821","reported_name":"Haas Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-10T23:20:53.000Z","date":"2025-06-06","kind":"grant","planned":false,"acquired":true,"shares":1209,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 6, 2025. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant."}],"balance_after":6606,"source":{"system":"sec-edgar","filing":"0002001011-25-000040","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101125000040/edgardoc.xml","form_type":"4"}},{"id":1356943,"issuer":{"id":85437,"kind":"organization","name":"Syros Pharmaceuticals, Inc.","symbol":"SYRS"},"owners":[{"id":23537,"kind":"person","name":"Haas Jason","position":1,"cik":"0001883821","reported_name":"Haas Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-11-20T17:00:07.000Z","date":"2024-11-18","kind":"sale","planned":false,"acquired":false,"shares":137803,"price":0.2103,"value":28979.9709,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.19 to $0.2295, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950170-24-129378","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1556263/000095017024129378/ownership.xml","form_type":"4"}},{"id":1376911,"issuer":{"id":85437,"kind":"organization","name":"Syros Pharmaceuticals, Inc.","symbol":"SYRS"},"owners":[{"id":23537,"kind":"person","name":"Haas Jason","position":1,"cik":"0001883821","reported_name":"Haas Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2024-11-04T17:01:22.000Z","date":"2024-10-31","kind":"exercise","planned":true,"acquired":false,"shares":18875,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Represents a restricted stock unit award granted on October 6, 2022. These restricted stock units vested as to one half (50%) of the shares on October 31, 2023, and as to one half (50%) of the shares on October 31, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Represents a restricted stock unit award granted on October 6, 2022. These restricted stock units vested as to one half (50%) of the shares on October 31, 2023, and as to one half (50%) of the shares on October 31, 2024."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":18875},"source":{"system":"sec-edgar","filing":"0000950170-24-120869","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1556263/000095017024120869/ownership.xml","form_type":"4"}},{"id":1376910,"issuer":{"id":85437,"kind":"organization","name":"Syros Pharmaceuticals, Inc.","symbol":"SYRS"},"owners":[{"id":23537,"kind":"person","name":"Haas Jason","position":1,"cik":"0001883821","reported_name":"Haas Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-11-04T17:01:22.000Z","date":"2024-10-31","kind":"tax_withholding","planned":true,"acquired":false,"shares":5624,"price":2.09,"value":11754.16,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares used to cover tax withholding on a restricted stock unit release."}],"balance_after":137803,"source":{"system":"sec-edgar","filing":"0000950170-24-120869","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1556263/000095017024120869/ownership.xml","form_type":"4"}},{"id":1376909,"issuer":{"id":85437,"kind":"organization","name":"Syros Pharmaceuticals, Inc.","symbol":"SYRS"},"owners":[{"id":23537,"kind":"person","name":"Haas Jason","position":1,"cik":"0001883821","reported_name":"Haas Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-11-04T17:01:22.000Z","date":"2024-10-31","kind":"exercise","planned":true,"acquired":true,"shares":18875,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock received upon vesting of a restricted stock unit award."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares of common stock received upon vesting of a restricted stock unit award."}],"balance_after":143427,"source":{"system":"sec-edgar","filing":"0000950170-24-120869","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1556263/000095017024120869/ownership.xml","form_type":"4"}},{"id":1408392,"issuer":{"id":85437,"kind":"organization","name":"Syros Pharmaceuticals, Inc.","symbol":"SYRS"},"owners":[{"id":23537,"kind":"person","name":"Haas Jason","position":1,"cik":"0001883821","reported_name":"Haas Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-09-12T17:00:03.000Z","date":"2024-09-12","kind":"purchase","planned":false,"acquired":true,"shares":45344,"price":1.6762,"value":76005.6128,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.62 to $1.69, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range."}],"balance_after":124552,"source":{"system":"sec-edgar","filing":"0000950170-24-105995","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1556263/000095017024105995/ownership.xml","form_type":"4"}},{"id":1408391,"issuer":{"id":85437,"kind":"organization","name":"Syros Pharmaceuticals, Inc.","symbol":"SYRS"},"owners":[{"id":23537,"kind":"person","name":"Haas Jason","position":1,"cik":"0001883821","reported_name":"Haas Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-09-12T17:00:03.000Z","date":"2024-09-11","kind":"purchase","planned":false,"acquired":true,"shares":19293,"price":1.5781,"value":30446.2833,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.55 to $1.60, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range."}],"balance_after":79208,"source":{"system":"sec-edgar","filing":"0000950170-24-105995","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1556263/000095017024105995/ownership.xml","form_type":"4"}},{"id":1408390,"issuer":{"id":85437,"kind":"organization","name":"Syros Pharmaceuticals, Inc.","symbol":"SYRS"},"owners":[{"id":23537,"kind":"person","name":"Haas Jason","position":1,"cik":"0001883821","reported_name":"Haas Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-09-12T17:00:03.000Z","date":"2024-09-10","kind":"purchase","planned":false,"acquired":true,"shares":35363,"price":1.5493,"value":54787.8959,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.50 to $1.57, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range."}],"balance_after":59915,"source":{"system":"sec-edgar","filing":"0000950170-24-105995","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1556263/000095017024105995/ownership.xml","form_type":"4"}},{"id":1476310,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":23537,"kind":"person","name":"Haas Jason","position":1,"cik":"0001883821","reported_name":"Haas Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2024-06-19T01:26:37.000Z","date":"2024-06-14","kind":"grant","planned":false,"acquired":true,"shares":5444,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 14, 2024. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant."}],"balance_after":5444,"derivative":{"exercise_price":80.06,"expiration_date":"2034-06-14","underlying":"Common Stock","underlying_shares":5444},"source":{"system":"sec-edgar","filing":"0002001011-24-000057","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101124000057/edgardoc.xml","form_type":"4"}},{"id":1476309,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":23537,"kind":"person","name":"Haas Jason","position":1,"cik":"0001883821","reported_name":"Haas Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-19T01:26:37.000Z","date":"2024-06-14","kind":"grant","planned":false,"acquired":true,"shares":1252,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 14, 2024. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant."}],"balance_after":5397,"source":{"system":"sec-edgar","filing":"0002001011-24-000057","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101124000057/edgardoc.xml","form_type":"4"}},{"id":1552797,"issuer":{"id":85437,"kind":"organization","name":"Syros Pharmaceuticals, Inc.","symbol":"SYRS"},"owners":[{"id":23537,"kind":"person","name":"Haas Jason","position":1,"cik":"0001883821","reported_name":"Haas Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2024-04-02T16:54:49.000Z","date":"2024-03-31","kind":"exercise","planned":false,"acquired":false,"shares":13333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Represents a restricted stock unit award granted on February 16, 2023. These restricted stock units vest in three equal annual installments commencing on March 31, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Represents a restricted stock unit award granted on February 16, 2023. These restricted stock units vest in three equal annual installments commencing on March 31, 2024."}],"balance_after":26667,"derivative":{"underlying":"Common Stock","underlying_shares":13333},"source":{"system":"sec-edgar","filing":"0000950170-24-040289","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1556263/000095017024040289/ownership.xml","form_type":"4"}},{"id":1552796,"issuer":{"id":85437,"kind":"organization","name":"Syros Pharmaceuticals, Inc.","symbol":"SYRS"},"owners":[{"id":23537,"kind":"person","name":"Haas Jason","position":1,"cik":"0001883821","reported_name":"Haas Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2024-04-02T16:54:49.000Z","date":"2024-03-31","kind":"exercise","planned":false,"acquired":false,"shares":2000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Represents a restricted stock unit award granted on February 15, 2022. These restricted stock units vest in four equal annual installments commencing on March 31, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Represents a restricted stock unit award granted on February 15, 2022. These restricted stock units vest in four equal annual installments commencing on March 31, 2023."}],"balance_after":4000,"derivative":{"underlying":"Common Stock","underlying_shares":2000},"source":{"system":"sec-edgar","filing":"0000950170-24-040289","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1556263/000095017024040289/ownership.xml","form_type":"4"}},{"id":1552795,"issuer":{"id":85437,"kind":"organization","name":"Syros Pharmaceuticals, Inc.","symbol":"SYRS"},"owners":[{"id":23537,"kind":"person","name":"Haas Jason","position":1,"cik":"0001883821","reported_name":"Haas Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-04-02T16:54:49.000Z","date":"2024-04-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":4732,"price":5.12,"value":24227.84,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares used to cover tax withholding upon the release of restricted stock units."}],"balance_after":24552,"source":{"system":"sec-edgar","filing":"0000950170-24-040289","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1556263/000095017024040289/ownership.xml","form_type":"4"}},{"id":1552794,"issuer":{"id":85437,"kind":"organization","name":"Syros Pharmaceuticals, Inc.","symbol":"SYRS"},"owners":[{"id":23537,"kind":"person","name":"Haas Jason","position":1,"cik":"0001883821","reported_name":"Haas Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-04-02T16:54:49.000Z","date":"2024-03-31","kind":"exercise","planned":false,"acquired":true,"shares":13333,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock received upon vesting of a restricted stock unit award."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares of common stock received upon vesting of a restricted stock unit award."}],"balance_after":29284,"source":{"system":"sec-edgar","filing":"0000950170-24-040289","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1556263/000095017024040289/ownership.xml","form_type":"4"}},{"id":1552793,"issuer":{"id":85437,"kind":"organization","name":"Syros Pharmaceuticals, Inc.","symbol":"SYRS"},"owners":[{"id":23537,"kind":"person","name":"Haas Jason","position":1,"cik":"0001883821","reported_name":"Haas Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-04-02T16:54:49.000Z","date":"2024-03-31","kind":"exercise","planned":false,"acquired":true,"shares":2000,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock received upon vesting of a restricted stock unit award."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares of common stock received upon vesting of a restricted stock unit award."}],"balance_after":15951,"source":{"system":"sec-edgar","filing":"0000950170-24-040289","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1556263/000095017024040289/ownership.xml","form_type":"4"}},{"id":1751069,"issuer":{"id":85437,"kind":"organization","name":"Syros Pharmaceuticals, Inc.","symbol":"SYRS"},"owners":[{"id":23537,"kind":"person","name":"Haas Jason","position":1,"cik":"0001883821","reported_name":"Haas Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2023-11-02T16:53:32.000Z","date":"2023-10-31","kind":"exercise","planned":false,"acquired":false,"shares":18875,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Represents a restricted stock unit award granted on October 6, 2022. These restricted stock units vested as to one half (50%) of the shares on October 31, 2023, and are scheduled to vest as to one half (50%) of the shares on October 31, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Represents a restricted stock unit award granted on October 6, 2022. These restricted stock units vested as to one half (50%) of the shares on October 31, 2023, and are scheduled to vest as to one half (50%) of the shares on October 31, 2024."}],"balance_after":18875,"derivative":{"underlying":"Common Stock","underlying_shares":18875},"source":{"system":"sec-edgar","filing":"0001209191-23-054172","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1556263/000120919123054172/doc4.xml","form_type":"4"}},{"id":1751068,"issuer":{"id":85437,"kind":"organization","name":"Syros Pharmaceuticals, Inc.","symbol":"SYRS"},"owners":[{"id":23537,"kind":"person","name":"Haas Jason","position":1,"cik":"0001883821","reported_name":"Haas Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-11-02T16:53:32.000Z","date":"2023-11-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":6301,"price":2.22,"value":13988.22,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares used to cover tax withholding on a restricted stock unit release."}],"balance_after":13951,"source":{"system":"sec-edgar","filing":"0001209191-23-054172","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1556263/000120919123054172/doc4.xml","form_type":"4"}},{"id":1751067,"issuer":{"id":85437,"kind":"organization","name":"Syros Pharmaceuticals, Inc.","symbol":"SYRS"},"owners":[{"id":23537,"kind":"person","name":"Haas Jason","position":1,"cik":"0001883821","reported_name":"Haas Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-11-02T16:53:32.000Z","date":"2023-10-31","kind":"exercise","planned":false,"acquired":true,"shares":18875,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock received upon vesting of a restricted stock unit award."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares of common stock received upon vesting of a restricted stock unit award."}],"balance_after":20252,"source":{"system":"sec-edgar","filing":"0001209191-23-054172","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1556263/000120919123054172/doc4.xml","form_type":"4"}},{"id":1857830,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":23537,"kind":"person","name":"Haas Jason","position":1,"cik":"0001883821","reported_name":"Haas Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2023-06-13T22:53:48.000Z","date":"2023-06-09","kind":"grant","planned":false,"acquired":true,"shares":5461,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 9, 2023. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant."}],"balance_after":5461,"derivative":{"exercise_price":73.76,"expiration_date":"2033-06-09","underlying":"Common Stock","underlying_shares":5461},"source":{"system":"sec-edgar","filing":"0000886163-23-000039","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/886163/000088616323000039/edgardoc.xml","form_type":"4"}},{"id":1857829,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":23537,"kind":"person","name":"Haas Jason","position":1,"cik":"0001883821","reported_name":"Haas Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-13T22:53:48.000Z","date":"2023-06-09","kind":"grant","planned":false,"acquired":true,"shares":1142,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 9, 2023. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant."}],"balance_after":4145,"source":{"system":"sec-edgar","filing":"0000886163-23-000039","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886163/000088616323000039/edgardoc.xml","form_type":"4"}},{"id":1926929,"issuer":{"id":85437,"kind":"organization","name":"Syros Pharmaceuticals, Inc.","symbol":"SYRS"},"owners":[{"id":23537,"kind":"person","name":"Haas Jason","position":1,"cik":"0001883821","reported_name":"Haas Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2023-04-04T18:57:29.000Z","date":"2023-03-31","kind":"exercise","planned":false,"acquired":false,"shares":2000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Represents a restricted stock unit award granted on February 15, 2022. These restricted stock units vest in four equal annual installments commencing on March 31, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Represents a restricted stock unit award granted on February 15, 2022. These restricted stock units vest in four equal annual installments commencing on March 31, 2023."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On September 16, 2022, the issuer effected a 1-for-10 reverse stock split of its common stock (the \"Reverse Stock Split\"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split."}],"balance_after":6000,"derivative":{"underlying":"Common Stock","underlying_shares":2000},"source":{"system":"sec-edgar","filing":"0001209191-23-022979","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1556263/000120919123022979/doc4.xml","form_type":"4"}},{"id":1926928,"issuer":{"id":85437,"kind":"organization","name":"Syros Pharmaceuticals, Inc.","symbol":"SYRS"},"owners":[{"id":23537,"kind":"person","name":"Haas Jason","position":1,"cik":"0001883821","reported_name":"Haas Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-04-04T18:57:29.000Z","date":"2023-04-03","kind":"tax_withholding","planned":false,"acquired":false,"shares":623,"price":2.58,"value":1607.34,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents shares used to cover tax withholding on a restricted stock unit release."}],"balance_after":1377,"source":{"system":"sec-edgar","filing":"0001209191-23-022979","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1556263/000120919123022979/doc4.xml","form_type":"4"}},{"id":1926927,"issuer":{"id":85437,"kind":"organization","name":"Syros Pharmaceuticals, Inc.","symbol":"SYRS"},"owners":[{"id":23537,"kind":"person","name":"Haas Jason","position":1,"cik":"0001883821","reported_name":"Haas Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-04-04T18:57:29.000Z","date":"2023-03-31","kind":"exercise","planned":false,"acquired":true,"shares":2000,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock received upon vesting of a restricted stock unit award."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares of common stock received upon vesting of a restricted stock unit award."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On September 16, 2022, the issuer effected a 1-for-10 reverse stock split of its common stock (the \"Reverse Stock Split\"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split."}],"balance_after":2000,"source":{"system":"sec-edgar","filing":"0001209191-23-022979","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1556263/000120919123022979/doc4.xml","form_type":"4"}},{"id":2002898,"issuer":{"id":85437,"kind":"organization","name":"Syros Pharmaceuticals, Inc.","symbol":"SYRS"},"owners":[{"id":23537,"kind":"person","name":"Haas Jason","position":1,"cik":"0001883821","reported_name":"Haas Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2023-02-21T16:21:30.000Z","date":"2023-02-16","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents the contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These RSUs will vest as to one third (1/3rd) of the shares underlying the award on March 31, 2024 and as to an additional one third (1/3rd) of such shares at the end of each successive year thereafter."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"These RSUs will vest as to one third (1/3rd) of the shares underlying the award on March 31, 2024 and as to an additional one third (1/3rd) of such shares at the end of each successive year thereafter."}],"balance_after":40000,"derivative":{"underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001209191-23-011162","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1556263/000120919123011162/doc4.xml","form_type":"4"}},{"id":2138960,"issuer":{"id":85437,"kind":"organization","name":"Syros Pharmaceuticals, Inc.","symbol":"SYRS"},"owners":[{"id":23537,"kind":"person","name":"Haas Jason","position":1,"cik":"0001883821","reported_name":"Haas Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2022-10-11T16:37:27.000Z","date":"2022-10-06","kind":"grant","acquired":true,"shares":37750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit (\"RSU\") represents the contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These RSUs will vest as to one half (50%) of the shares on October 31, 2023, and as to one half (50%) of the shares on October 31, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"These RSUs will vest as to one half (50%) of the shares on October 31, 2023, and as to one half (50%) of the shares on October 31, 2024."}],"balance_after":37750,"derivative":{"underlying":"Common Stock","underlying_shares":37750},"source":{"system":"sec-edgar","filing":"0001209191-22-053316","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1556263/000120919122053316/doc4.xml","form_type":"4"}},{"id":2138959,"issuer":{"id":85437,"kind":"organization","name":"Syros Pharmaceuticals, Inc.","symbol":"SYRS"},"owners":[{"id":23537,"kind":"person","name":"Haas Jason","position":1,"cik":"0001883821","reported_name":"Haas Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2022-10-11T16:37:27.000Z","date":"2022-10-06","kind":"grant","acquired":true,"shares":49750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option becomes exercisable as to one half (50%) of the shares on October 31, 2023, and as to one half (50%) of the shares on October 31, 2024."}],"balance_after":49750,"derivative":{"exercise_price":6.73,"expiration_date":"2032-10-05","underlying":"Common Stock","underlying_shares":49750},"source":{"system":"sec-edgar","filing":"0001209191-22-053316","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1556263/000120919122053316/doc4.xml","form_type":"4"}},{"id":2218940,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":23537,"kind":"person","name":"Haas Jason","position":1,"cik":"0001883821","reported_name":"Haas Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2022-06-30T22:32:37.000Z","date":"2022-06-29","kind":"grant","acquired":true,"shares":5907,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option becomes exercisable in 3 successive annual installments upon completion of each calendar year of service beginning on the grant date."}],"balance_after":5907,"derivative":{"exercise_price":88.48,"expiration_date":"2032-06-29","underlying":"Common Stock","underlying_shares":5907},"source":{"system":"sec-edgar","filing":"0000886163-22-000103","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/886163/000088616322000103/edgardoc.xml","form_type":"4"}},{"id":2218939,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":23537,"kind":"person","name":"Haas Jason","position":1,"cik":"0001883821","reported_name":"Haas Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-06-30T22:32:37.000Z","date":"2022-06-29","kind":"grant","acquired":true,"shares":1750,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":1750,"source":{"system":"sec-edgar","filing":"0000886163-22-000103","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886163/000088616322000103/edgardoc.xml","form_type":"4"}},{"id":2387548,"issuer":{"id":85437,"kind":"organization","name":"Syros Pharmaceuticals, Inc.","symbol":"SYRS"},"owners":[{"id":23537,"kind":"person","name":"Haas Jason","position":1,"cik":"0001883821","reported_name":"Haas Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2022-02-17T16:07:01.000Z","date":"2022-02-15","kind":"grant","acquired":true,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit (\"RSU\") represents the contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These RSUs will vest in four equal annual installments commencing on March 31, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"These RSUs will vest in four equal annual installments commencing on March 31, 2023."}],"balance_after":80000,"derivative":{"underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0001209191-22-010707","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1556263/000120919122010707/doc4.xml","form_type":"4"}},{"id":2387547,"issuer":{"id":85437,"kind":"organization","name":"Syros Pharmaceuticals, Inc.","symbol":"SYRS"},"owners":[{"id":23537,"kind":"person","name":"Haas Jason","position":1,"cik":"0001883821","reported_name":"Haas Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2022-02-17T16:07:01.000Z","date":"2022-02-15","kind":"grant","acquired":true,"shares":125000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option becomes exercisable as to one quarter (1/4th) of the shares on February 28, 2023, with the remainder vesting in monthly installments equal to one forty-eighth (1/48th) of the original number of shares at the end of each of the next thirty-six (36) months thereafter."}],"balance_after":125000,"derivative":{"exercise_price":1.59,"expiration_date":"2032-02-14","underlying":"Common Stock","underlying_shares":125000},"source":{"system":"sec-edgar","filing":"0001209191-22-010707","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1556263/000120919122010707/doc4.xml","form_type":"4"}},{"id":2543171,"issuer":{"id":85437,"kind":"organization","name":"Syros Pharmaceuticals, Inc.","symbol":"SYRS"},"owners":[{"id":23537,"kind":"person","name":"Haas Jason","position":1,"cik":"0001883821","reported_name":"Haas Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2021-10-13T16:06:51.000Z","date":"2021-10-12","kind":"grant","acquired":true,"shares":750000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option becomes exercisable as to one quarter (1/4th) of the shares on October 12, 2022, with the remainder vesting in monthly installments equal to one forty-eighth (1/48th) of the original number of shares at the end of each of the next thirty-six (36) months thereafter."}],"balance_after":750000,"derivative":{"exercise_price":4.54,"expiration_date":"2031-10-11","underlying":"Common Stock","underlying_shares":750000},"source":{"system":"sec-edgar","filing":"0001209191-21-060358","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1556263/000120919121060358/doc4.xml","form_type":"4"}}]}